Matthew R. Henn, See Remarks at Seres Therapeutics, Inc. (MCRB), sold 891 shares at $0.94 ($838) on 2024-05-15, disclosed to the SEC on 2024-05-17.
Scheduled sale ($838) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| MCRB | SELL | 2024-10-29 | $3K | — | Filing → |
| MCRB | SELL | 2024-08-19 | $775 | — | Filing → |
| MCRB | SELL | 2024-02-16 | $5K | — | Filing → |